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Abstract
Background/Aims: The current diagnostic workup of Cush-
ing’s syndrome (CS) requires various tests which only cap-
ture short-term cortisol exposure, whereas patients with en-
dogenous CS generally have elevated cortisol levels over 
longer periods of time. Scalp hair assessment has emerged 
as a convenient test in capturing glucocorticoid concentra-
tions over long periods of time. The aim of this multicenter, 
multinational, prospective, case-control study was to evalu-
ate the diagnostic efficacy of scalp hair glucocorticoids in 
screening of endogenous CS. Methods: We assessed the di-
agnostic performances of hair cortisol (HairF), hair cortisone 
(HairE), and the sum of both (sumHairF+E), as measured by 
a state-of-the-art LC-MS/MS technique, in untreated pa-
tients with confirmed endogenous CS (n = 89) as well as in 
community controls (n = 295) from the population-based 
Lifelines cohort study. Results: Both glucocorticoids were 
significantly elevated in CS patients when compared to con-
trols. A high diagnostic efficacy was found for HairF (area un-
der the curve 0.87 [95% CI: 0.83–0.92]), HairE (0.93 [0.89–
0.96]), and sumHairF+E (0.92 [0.88–0.96]) (all p < 0.001). The 
participants were accurately classified at the optimal cutoff 
threshold in 86% of the cases (81% sensitivity, 88% specific-
ity, and 94% negative predictive value [NPV]) by HairF, in 
90% of the cases (87% sensitivity, 90% specificity, and 96% 
NPV) by HairE, and in 87% of the cases (86% sensitivity, 88% 
specificity, and 95% NPV) by the sumHairF+E. HairE was 
shown to be the most accurate in differentiating CS patients 
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from controls. Conclusion: Scalp hair glucocorticoids, espe-
cially hair cortisone, can be seen as a promising biomarker in 
screening for CS. Its convenience in collection and workup 
additionally makes it feasible for first-line screening.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Cushing’s syndrome (CS) results from excessive expo-
sure to glucocorticoid hormones and is associated with 
significant morbidity and mortality [1]. After exclusion 
of exogenous CS caused by glucocorticoid-containing 
drugs, a variety of endogenous diseases can give rise to 
increased secretion of cortisol. Approximately 70% of the 
cases of endogenous CS are caused by a pituitary adeno-
ma producing excessive ACTH, stimulating the adrenal 
to produce cortisol (i.e., Cushing’s disease). The remain-
der of endogenous CS cases mostly consist of adrenal 
causes and ectopic ACTH production [1].
Endogenous CS is rare but often presents with com-
mon and therefore nonspecific signs and symptoms such 
as weight gain, fatigue, metabolic syndrome features, and 
depression [2]. Features more specific for CS include easy 
bruising, facial plethora, and proximal myopathy, but 
these do not occur in all patients [3]. This clinical dilem-
ma can cause a significant delay in diagnosis, which is 
often made when the condition has been existing for an 
extended period of time and patients display multiple 
signs and symptoms of CS. Current guidelines recom-
mend three different first-line screening tests: 24-h uri-
nary free cortisol (UFC), late-night salivary cortisol 
(LNSC), and the 1-mg dexamethasone suppression test 
[4]. All three tests rely on patient compliance for the col-
lection of samples or drug intake, and their limitations 
often necessitate repeated testing. Furthermore, they may 
be influenced by several factors such as kidney function 
(for UFC), gingival microtrauma (for LNSC), and drug 
use (for the dexamethasone suppression test).
Recently, we reported on the largest study thus far us-
ing measurements of scalp hair cortisol in patients with 
CS [5]. Scalp hair offers information about integrated 
cortisol exposure over months of time [6]. This may be 
particularly valuable in CS, where cortisol production 
may often vary across days. In our study, hair cortisol 
provided a 93% sensitivity and 91% specificity for CS, 
comparing well to first-line tests [5]. Furthermore, hair 
analysis can be used to create retrospective timelines of 
cortisol exposure, which can be helpful in cases of cyclic 
CS [7, 8].
All studies measuring hair cortisol in CS thus far relied 
on immunoassays to quantify cortisol. A recent advance 
in the development of hair steroid analysis is hair steroid 
profiling using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Recently, we have validated 
a method which measures hair values of cortisol, corti-
sone, testosterone, androstenedione, dehydroepiandros-
terone sulfate, and 17α-hydroxyprogesterone [9]. In con-
trast to immunoassays, LC-MS/MS is less prone to inter-
ference, offers higher sensitivity, and can be used to 
measure multiple steroids simultaneously. The aim of 
this study was to assess the diagnostic efficacy of hair cor-
tisol (HairF) and cortisone (HairE) measured by LC-MS/
MS in two independently collected cohorts of patients 
with endogenous CS.
Subjects and Methods
Study Participants
Our study population consisted of 295 controls from the gen-
eral Dutch population, which had also been included in our previ-
ous study [10], and 89 patients with proven endogenous CS. All 
controls were recruited from Lifelines, which is a multidisci-
plinary, prospective, population-based cohort study examining in 
a unique three-generation design the health and health-related be-
haviors of 167,729 persons living in the north of the Netherlands. 
It employs a broad range of investigative procedures in assessing 
the biomedical, sociodemographic, behavioral, physical, and psy-
chological factors which contribute to the health and disease of the 
general population, with a special focus on multimorbidity and 
complex genetics [11]. Patients were recruited from two clinic 
sites, one in the Netherlands (Erasmus MC, Rotterdam; n = 19) and 
one in Germany (Klinikum der Ludwig-Maximilians-Universität 
München, Munich; n = 70). Diagnostic workup was performed ac-
cording to the guideline [4] and the diagnosis of CS, de novo or 
recurrent, was biochemically established by experienced endocri-
nologists and proven by surgery and/or additional investigations 
(e.g., bilateral inferior petrosal sinus sampling).
Scalp Hair Measurements
In all participants, a scalp hair sample of approximately 100–
150 hairs was collected from the posterior vertex. The hair was cut 
as close to the scalp as possible and after sample collection stored 
in an envelope in the dark at room temperature. The protocol for 
hair processing and analysis was adapted from the previous meth-
od described in detail elsewhere [9]. In short, approximately 20 mg 
of the proximal 3 cm (or the entire length of the hair sample, if the 
hair was shorter than 3 cm) was weighed and cut into 1-cm-long 
pieces. The hair was washed in 2 mL of LCMS-grade isopropanol 
for 2 min and allowed to fully dry. Steroids were extracted over-
night in 1.4 mL of LCMS-grade methanol, and 100 μL of cortisol-
d3 and cortisone-d8 as internal standards for 18 h at 25  ° C while 
the samples were being gently shaken. After extraction, hair sam-
ples were centrifuged at 4,369 g (4,500 rpm) for 5 min, and 900 μL 
of the extract was transferred to a clean tube. We then added 750 
μL of methanol to the hair samples, which were spun down again, 
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after which another 900 μL of extract was transferred to the tubes 
with the extract. The extracts were evaporated under a continuous 
nitrogen stream at 37  ° C, reconstituted in 1 mL of purified water 
and 20 μL of methanol, and purified using solid-phase extraction.
Cortisol and cortisone concentrations were subsequently 
quantified by LC-MS/MS using a Xevo TQ-S system (Wates, Mil-
ford, MA, USA). HairF and HairE were successfully determined in 
91 and 97% of the study participants. Data on both hair glucocor-
ticoids were available for 89% of the study population. The interas-
say coefficient of variation for cortisol and cortisone was 14.8 and 
15.3%, respectively. The intra-assay coefficient of variation for cor-
tisol and cortisone was < 11 and < 8%, respectively. The lower lim-
it of quantification of cortisol and cortisone was < 1.3 and < 9.3 pg/
mg, respectively. For research purposes, HairF and HairE mea-
surements below the lower limit of quantification were included in 
the analyses as quantitative measures, since no recognized substi-
tution method exists.
Statistical Analysis
We used SPSS version 24 (IBM Corp., Armonk, NY, USA) and 
RStudio version 1.0.136 (RStudio, Inc., Boston, MA, USA) with the 
pROC package [12] for the statistical analyses. The hair glucocor-
ticoid values were logarithmically transformed to achieve a normal 
distribution and are reported as geometric means and 95% CI. The 
baseline characteristics were analyzed using ANCOVA if continu-
ous, and using χ2 tests if categorical. Associations between HairF 
and HairE were assessed by Pearson’s correlation. The diagnostic 
efficacy of HairF, HairE, and the sum of HairF and HairE 
(sumHairF+E) for CS screening was assessed using receiver oper-
ating characteristic (ROC) curves.
Optimal cutoffs, defined as the curve points closest to the top-
left corner, were initially determined for cohorts 1 and 2 separate-
ly. For the main analyses, both cohorts were combined and optimal 
cutoff values were determined for the complete population. De-
Long’s test was used to compare ROC curves between the two co-
horts. Paired analyses were additionally performed to assess the 
discriminating ability of the different outcomes relative to each 
other. Moreover, we computed the diagnostic accuracy (i.e., the 
percentage of correctly classified subjects) and other diagnostic 
performance parameters (i.e., sensitivity, specificity, positive pre-
dictive value [PPV], negative predictive value [NPV], positive like-
lihood ratio [LR+], and negative likelihood ratio [LR–]). Given the 
intraindividual and interassay coefficients of variation, we addi-
tionally calculated diagnostic performance parameters at 15 and 
30% higher and lower levels than the optimal cutoffs. Further-
more, we performed sensitivity analyses in order to account for 
potential effects of exogenous glucocorticoids on hair glucocorti-
coid concentrations [10]. We repeated the main ROC analyses 
with only nonusers in the control cohort. This resulted in exclu-
sion of a total of 38 controls who had used any type of exogenous 
glucocorticoids in the previous 3 months. Among these partici-
pants, hair analyses were successful in 36/38 for HairF and 
sumHairF+E, and in 37/38 for HairE. All outcomes were consid-
ered statistically significant in case of a p value < 0.05.
Results
Descriptive Characteristics and Hair Glucocorticoid 
Concentrations
The subjects’ characteristics and concentrations of 
hair glucocorticoids are shown in Table 1 and Figure 1. 
On average, the controls were younger (42.3 years) than 
the patients (50.2 years). The majority of the participants 
were women in both the control group (74.6%) and the 
CS group (74.2%). Hair glucocorticoids stratified by sex 
are shown in online supplementary Table S1 (see www.
karger.com/doi/10.1159/000498886 for all online suppl. 
material). In general, men had higher levels on all mea-
sures; however, significant sex differences in the three in-
dices were only present in the controls. Both male and 
female CS patients had higher values than the controls of 
same sex (all p < 0.001). Overall, there was a strong linear 
association between HairF and HairE (r = 0.821, p < 
0.001). The geometric mean HairF was higher in the CS 
patients of cohort 1 (17.3 pg/mg [95% CI: 9.5–31.3]) and 
cohort 2 (11.7 pg/mg [95% CI: 8.5–16.2]) than in the con-
trols (2.7 pg/mg [95% CI: 2.5–2.9]) (both p < 0.001). 
HairE was also significantly higher in the patients (cohort 
1: 37.9 pg/mg [95% CI: 21.7–66.3]; cohort 2: 40.9 pg/mg 
Table 1. Descriptive characteristics and hair glucocorticoids of the controls and Cushing’s syndrome patients
Controls 
(n = 295)
Cushing’s syndrome patients
cohort 1 (n = 19) cohort 2 (n = 70) combined (n = 89)
Female 220 (74.6) 16 (84.2) 50 (71.4) 66 (74.2)
Age, years 42.3±11.5 44.2±16.7 51.8±15.4 50.2±15.9
Hair glucocorticoids, pg/mg
Hair cortisol (HairF) 2.7 (2.5–2.9) 17.3 (9.5–31.3) 11.7 (8.5–16.2) 12.7 (9.6–16.9)
Hair cortisone (HairE) 8.2 (7.8–8.7) 37.9 (21.7–66.3) 40.9 (30.8–54.4) 40.2 (31.4–51.5)
Sum hair glucocorticoids (sumHairF+E) 11.2 (10.6–12.0) 63.7 (39.4–102.9) 49.7 (38.1–65.0) 52.6 (41.8–66.2)
Data are shown as n (%), mean ± SD, or geometric mean (95% CI).
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[95% CI: 30.8–54.4]) than in the controls (8.2 pg/mg [95% 
CI: 7.8–8.7]) (both p < 0.001). The geometric mean of the 
sum of both hair glucocorticoids was also higher in the 
CS patients than in the controls. There were no statisti-
cally significant differences in hair glucocorticoids be-
tween the two patient cohorts.
Diagnostic Efficacy of Hair Glucocorticoids for 
Screening of CS
ROC curves with corresponding diagnostic perfor-
mance parameters for HairF, HairE, and sumHairF+E are 
depicted in Figure 2. Analyses stratified by sex are shown 
in online supplementary Figure S1. All three indices 
showed a strongly significant differentiating efficacy 
among CS patients from both cohorts separately and 
combined (p < 0.001 for all areas under the curve [AUCs]).
For HairF, an optimal cutoff of 4.7 pg/mg (AUC 0.87 
[95% CI: 0.83–0.92]) was observed, with an accuracy of 
86%, a sensitivity of 81%, and a specificity of 88%. A pos-
itive test result confirmed CS with 68% probability, 
whereas the NPV was 94%. In regard to HairE, the ROC 
analysis yielded an optimal cutoff of 13.8 pg/mg (AUC 
0.93 [0.89–0.96]). This allowed the correct identification 
of 74/85 CS patients and 261/289 controls, corresponding 
to 90% accuracy, 87% sensitivity, and 90% specificity. The 
PPV and NPV with HairE was 73 and 96%, respectively. 
The sum of both hair glucocorticoids also showed a high 
diagnostic efficacy with an AUC of 0.92 (95% CI: 0.88–
0.96). The optimal sumHairF+E cutoff was 18.9 pg/mg, 
with a corresponding sensitivity of 86% and a specificity 
of 88%. At this cutoff, 69/80 CS patients and 230/262 con-
trols were identified correctly, yielding an accuracy of 
87% with a PPV of 68% and an NPV of 95%.
In the context of sensitivity analyses to take potential 
influencing effects of glucocorticoid-containing drugs 
into account, we found nearly identical AUCs when only 
nonusers were considered as controls (p < 0.001 for all 
three indices; data not shown). Moreover, the optimal 
cutoff levels with corresponding sensitivity and specific-
ity were also roughly the same for HairF (4.7 pg/mg; 81% 
sensitivity, 87% specificity), HairE (13.8 pg/mg; 87% sen-
sitivity, 89% specificity), and sumHairF+E (16.2 pg/mg; 
89% sensitivity, 85% specificity). Diagnostic accuracy at 
these levels was 86% for HairF, 89% for HairE, and 86% 
for sumHairF+E.
The optimal cutoff for all outcomes was lower in co-
hort 2 than in cohort 1; however, only the sum of hair 
glucocorticoids was statistically significantly different in 
diagnostic efficacy between the two cohorts (Fig.  3). 
Paired ROC analysis of the hair glucocorticoids showed 
that HairE and sumHairF+E were more accurate than 
HairF in the screening of CS in the complete study popu-
lation (both p < 0.010; Fig. 4), whereas HairE was margin-
ally more accurate than the sum value (p = 0.041).
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Fig. 1. Distribution of hair glucocorticoid concentrations in con-
trols and Cushing’s syndrome patients. Hair cortisol (HairF), hair 
cortisone (HairE), and the sum of both (sumHairF+E) are shown 
for community controls, as well as for Cushing’s syndrome pa-
tients from two independent cohorts. The data for each group are 
summarized as the geometric mean with corresponding 95% CI. 
The solid black lines correspond to the optimal cutoff values, and 
the dashed lines above and below indicate levels corresponding to 
15 and 30% above and below the optimal cutoff values, respec-
tively.
Hair Glucocorticoids in Cushing’s 
Syndrome
175Neuroendocrinology 2019;109:171–178
DOI: 10.1159/000498886
Discussion
In this multicenter study, we evaluated, for the first time, 
the diagnostic efficacy of scalp hair cortisol and cortisone 
concentrations as measured by LC-MS/MS for the screen-
ing of CS in two independent patient cohorts. We showed 
that both glucocorticoids were significantly elevated in pa-
tients when compared to community controls, while there 
were no differences between the patient cohorts. With re-
spect to diagnostic performance, we found a high differen-
tiating capacity of HairF (accuracy 86%, sensitivity 81%, 
and specificity 88%), HairE (accuracy 90%, sensitivity 87%, 
and specificity 90%), and the sum of both (accuracy 87%, 
sensitivity 86%, and specificity 88%). Excluding users of 
exogenous glucocorticoids in the control cohort revealed 
no significant effects on these findings. Paired analyses 
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Fig. 2. Receiver operating characteristic curve analyses of the diag-
nostic performance of hair glucocorticoids for Cushing’s syn-
drome. The red dots refer to the OC value for screening of Cush-
ing’s syndrome. The table summarizes the different diagnostic per-
formance parameters at the OC level and other specified levels. 
AUC, area under the curve; HairE, hair cortisone concentrations; 
HairF, hair cortisol concentrations; sumHairF+E, sum of HairF 
and HairE; OC, optimal cutoff threshold; LR, likelihood ratio; 
NPV, negative predictive value; PPV, positive predictive value; 
Sens, sensitivity; Spec, specificity.
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showed that HairE was more accurate than HairF or the 
sum of both in distinguishing patients from controls.
Assessment of cortisol concentrations in scalp hair has 
previously been performed by us and others to compare 
levels between CS patients and controls [5, 7, 8, 13, 14]. 
Published studies consistently showed clearly elevated 
levels in patients in the proximal 1- and 3-cm hair seg-
ments. Recently, we have also investigated the diagnostic 
efficacy of HairF in distinguishing CS patients from 
healthy controls, as well as patients suspected of CS but in 
whom the diagnosis was eventually excluded. High sensi-
tivity and specificity were observed with similar optimal 
cutoffs for both analyses [5]. However, this and previous 
studies have only analyzed HairF and have performed 
analyses by immunoassay, which is, among others, prone 
to cross-reactivity and is inferior to LC-MS/MS with re-
spect to selectivity and detection. Findings of local pro-
duction of 11β-hydroxysteroid dehydrogenase (11β-HSD) 
types 1 and 2 – which are, respectively, responsible for the 
conversion of cortisone into cortisol and vice versa – in 
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Fig. 4. Paired analyses for differences in diagnostic efficacy between hair glucocorticoids for screening of Cush-
ing’s syndrome. Hair cortisone (HairE) was more accurate than hair cortisol (HairF) and the sum of both gluco-
corticoids (sumHairF+E) in differentiating patients with Cushing’s syndrome from controls. sumHairF+E was 
also statistically significantly better than HairF with respect to diagnostic efficacy.
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Fig. 3. Comparison of receiver operating characteristic curves for screening of Cushing’s syndrome by hair glu-
cocorticoids between two independent patient cohorts. HairE, hair cortisone concentrations; HairF, hair cortisol 
concentrations; sumHairF+E, sum of HairF and HairE.
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skin, hair follicles, and other cutaneous appendages [15–
17] also complicate the interpretation of prior findings in 
CS patients. It therefore remains questionable whether the 
measured hair cortisol concentrations only reflect the ac-
tual past exposure to cortisol or whether these are altered 
due to local conversion by 11β-HSDs.
Here, we showed for the first time that HairF as well as 
HairE is elevated in CS patients and that both glucocorti-
coids possess a high diagnostic efficacy. Moreover, we 
showed a relatively better diagnostic performance of 
HairE in distinguishing patients from controls when com-
pared to HairF. Another test that might also be prone to 
local conversion effects is the first-line screening test with 
salivary cortisol – this because of the 11β-HSD2 activity in 
parotid tissue [17]. A previous study by Perogamvros et al. 
[18] focused on both salivary glucocorticoids in non-
cushingoid patients and found, similarly to the current 
work, higher concentrations of cortisone than of cortisol, 
whereas the opposite was true for the free fractions in se-
rum. Interestingly, sampling after adrenal stimulation 
with ACTH injection showed salivary cortisone to reflect 
free serum cortisol more accurately than salivary cortisol. 
An evaluation of salivary cortisol and cortisone in anoth-
er study with CS patients indeed revealed a high diagnos-
tic accuracy of both measures [19]. Additionally, a recent 
study by Kapoor et al. [20] with radiolabeled cortisol ex-
periments on primates confirmed that circulating cortisol 
is taken up in hair and can be measured. Importantly, the 
authors also showed that a substantial proportion of the 
administered cortisol was incorporated as cortisone. More 
research, however, is needed to understand the dynamics 
between cortisol and cortisone at the local level and to in-
vestigate the additional value of cortisone measurements.
The diagnostic efficacy of screening tests depends on 
the chosen cutoff value for differentiating patients from 
subjects without the disease. This makes it challenging to 
place our results in the context of the recommended tests. 
Nevertheless, Elamin et al. [21] have systematically sum-
marized and pooled the results of the traditional tests in 
the diagnostic workup of CS. Based on this, the diagnostic 
efficacy of hair glucocorticoids, especially of HairE, seems 
to be quite similar to that of midnight salivary cortisol 
(pooled LR+ 8.8 and LR– 0.1) and UFC (pooled LR+ 10.6 
and LR– 0.2), even though most of the included studies 
had a small population with a fairly high prevalence of CS 
[21]. Since the diagnosis of CS could not rely on a single 
screening test, further research should especially address 
the diagnostic effectiveness of hair glucocorticoids in 
combination with other recommended tests. Besides, as 
mentioned in the guideline and also observed here, there 
is a substantial proportion of false positives with the 
screening tests, due among other things to the high prev-
alence of (mild) hypercortisolistic cushingoid-like condi-
tions (e.g., psychiatric disorders, diabetes mellitus, and 
obesity) and the rare occurrence of CS [4]. Therefore, the 
recommendation to restrict testing to subjects with a high 
a priori probability of having CS could reasonably be ex-
tended to hair glucocorticoid assessment.
The current screening tests are subject to several difficul-
ties and limitations which are less severe or completely ab-
sent with scalp hair measurements. From the patient’s per-
spective, hair sampling is noninvasive and does not require 
following specific instructions (e.g., collection of urine out-
put for at least 24 consecutive hours for UFC) or impose 
restrictions (e.g., fasting or no teeth brushing before saliva 
collection for LNSC) as with the recommended tests; also, 
hair samples can be collected, stored, and posted by mail 
with ease, which is especially useful for patients who have 
to cover long distances to a clinic site. For care profession-
als, it is convenient that hair measurements are not depen-
dent on the time of day or patient compliance and are not 
influenced by acute stressors. The unique feature of these 
measurements of covering long-term glucocorticoid expo-
sure makes them additionally useful in the screening for 
cyclical CS. The current guideline recommends UFC or sal-
ivary cortisol measurements in case of suspicion of cyclical 
CS [4]; however, these tests can yield normal results when 
patients are screened after the periodical increase in cortisol 
levels. We previously demonstrated the usefulness of hair 
measurements in such situations in multiple patients who 
had normal screening test results at the time of evaluation 
but had retrospectively elevated cortisol concentrations in 
hair segments corresponding to the period of cushingoid 
signs and symptoms [7].
The large number of patients and controls and the 
multicenter evaluation are among the major strengths of 
the current work. Moreover, all hair glucocorticoid con-
centrations were determined with high sensitivity and 
specificity using a state-of-the-art LC-MS/MS technique. 
This study is, however, limited in the way that controls 
from the community were not screened for CS. Neverthe-
less, given the rarity of this disorder, with less than 5 cas-
es per million individuals [22], it is very unlikely that con-
trols were misclassified. Moreover, the results were not 
adjusted for potential confounders such as UV exposure 
[23], hair washing, or diabetes mellitus [24]. It is, how-
ever, questionable whether these factors would have sub-
stantially influenced the outcomes, because of the large 
(5–6 fold) differences between controls and CS patients 
in hair glucocorticoid levels.
Savas et al.Neuroendocrinology 2019;109:171–178178
DOI: 10.1159/000498886
In conclusion, scalp hair assessment for hair glucocor-
ticoids, in particular for cortisone concentrations, shows 
a high diagnostic efficacy in differentiating CS patients 
from controls. Because of its simplicity and noninvasive 
sampling, as well as its diagnostic performance, it may be 
seen as a promising biomarker and a potential addition 
to the armamentarium of CS screening tests. To allow the 
uniform use of fixed cutoff values, we recommend further 
efforts to standardize or harmonize results between inter-
national centers.
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